MedTrace Logo

Comparison of Different Doses of 131I in Severe Graves' Hyperthyroidism

NCT01039818 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2012-09-06

No results posted yet for this study

Summary

The purpose of this study is to determine whether higher doses of radioiodine increase treatment efficacy in severe Graves' disease.

Conditions

  • Graves Disease

Interventions

RADIATION

Radioiodine

A unique dose of 200µCi of ¹³¹I/ml/24-RAIU

RADIATION

Radioiodine

A unique dose of 250µCi of ¹³¹I/ml/24-RAIU

Sponsors & Collaborators

  • Federal University of Rio Grande do Sul

    collaborator OTHER

  • Hospital de Clinicas de Porto Alegre

    lead OTHER

Principal Investigators

  • Ana L Maia, MD, PhD · Thyroid Unit, Endocrine Division, Hospital de Clínicas de Porto Alegre

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1997-02-28
Primary Completion
2011-08-31
Completion
2011-08-31

Countries

  • Brazil

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01039818 on ClinicalTrials.gov